BillionToOne CEO and Cofounder Oguzhan Atay said that the firm’s prenatal testing business is already so profitable that “we do not need any additional capital to reach cash-flow positivity with fast growth.”
Read more here.
Media Coverage
Related News
View AllMedia Coverage
JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Read Article
Press Releases
BillionToOne’s UNITY Fetal Antigen NIPT Transforms Care in Maternity Health Deserts
Read Article
Media Coverage
BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards
Read Article
Press Releases
Leading Molecular Diagnostics Company BillionToOne Announces Three Executive Appointments Amid Rapid Growth
Read Article
Media Coverage
The Green Room Podcast from Obstetrics & Gynecology-Interview with Jennifer Hoskovec, MS, author of “Cell-Free DNA Analysis for the Determination of Fetal Red Blood Cell Antigen Genotype in Individuals With Alloimmunized Pregnancies.”
Read Article
Media Coverage
A Major Addition to Austin’s Life Science Ecosystem with the Expansion of BillionToOne
Read Article
Press Releases
Category Defining Molecular Diagnostics Company BillionToOne Further Solidifies its Long-Term Position by Securing $140 Million Non-Dilutive Financing with Oberland Capital
Read Article
Press Releases
BillionToOne Announces Green Journal Publication that Underscores the Role of cell-free DNA NIPT for Fetal Red Blood Cell Antigen Genotyping
Read Article
Media Coverage
Slice of Healthcare-BillionToOne Raises $130M In Series D Funding Round
Read Article
Media Coverage
Genomeweb-BillionToOne Raises $130M in Series D Financing Round
Read Article
